The cancellation of ongoing NIH-funded Alzheimer’s research grants is a serious setback in the fight against Alzheimer’s disease. Halting peer-reviewed studies wastes taxpayer investments, disrupts years of scientific progress, and delays the discoveries that millions of patients and families urgently need.
Alzheimer’s disease is one of our nation’s greatest public health challenges. Progress depends on sustained investment in research that improves prevention, diagnosis, and treatment, including studies that help us understand why the disease affects some populations and communities more than others. These are critical scientific questions that cannot be answered if research is interrupted.
We urge Congress and the Administration to restore funding for these studies and protect the integrity of the NIH scientific review process. Research funding decisions should be guided by scientific merit and public health impact, not political priorities.
Every delay in research means delays in identifying new risk factors, improving diagnostic tools, developing effective therapies, and ultimately delivering better outcomes for the millions of individuals and families affected by Alzheimer’s disease.
Every delay in Alzheimer’s research postpones hope for the millions of Americans living with the disease and those at risk.